Products
Methylprednisolone aceponate has been approved in many countries since 1991 and is commercially available as cream, ointment, and fatty ointment (Advantan).
Structure and properties
Methylprednisolone aceponate (C27H36O7, Mr = 472.6 g/mol) is a lipophilic and nonhalogenated glucocorticoid that is hydrolyzed in the skin by esterases to the active metabolite 6α-methylprednisolone-17-propionate.
Effects
Methylprednisolone aceponate (ATC D07AC14) has anti-inflammatory, vasoconstrictive, antiallergic, immunosuppressive, and antipruritic properties. The effects are due to binding to intracellular glucocorticoid receptors. Methylprednisolone aceponate belongs to strength class III.
Indications
- Atopic dermatitis
- Contact eczema
- Degenerative, dyshidrosiform, nummular, unclassified eczema, eczema in children.
Dosage
According to the professional information. The drugs are applied thinly once a day. Because of the potential for adverse effects, dermocorticoids should be used for as short a time as possible. If they are needed for a prolonged period, breaks in therapy must be taken or cortisone-free preparations must be used in the interim. Dermocorticoids should not be applied over large areas and should not be overdosed.
Contraindications
- Hypersensitivity
- Bacterial skin diseases
- Viral diseases of the skin
- Rosacea
- Perioral dermatitis
- Skin ulcers
- Acne
- Atrophic skin diseases
- Post-vaccinal skin reactions in the treatment area.
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include burning and itching at the application site. Improper use of dermocorticoids may result in skin damage such as thinning of the skin (atrophy), skin striae, and telangiectasias; see topical glucocorticoids.
